Managing Bone Health in Metastatic Breast Cancer

Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

• 类别